Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Delayed Nyse  -  04:03 2022-12-02 pm EST
126.99 USD   +0.79%
11/30Dow dips ahead of Powell speech; Nasdaq kept afloat by growth stocks
11/303M Company Confirms Earnings Guidance for the Fourth Quarter of 2022
11/30Transcript : 3M Company Presents at Credit Suisse’s 10th Annual Global Industrials Conference, Nov-30-2022 09:30 AM
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

3M completes sale of rights to Neoplast and Neobun brands and related assets in Thailand and certain other Southeast Asia countries

10/04/2022 | 07:38am EST

ST. PAUL - 3M (NYSE: MMM) today announced that it has completed the sale of its rights to the Neoplast and Neobun brands and related assets in Thailand and certain other Southeast Asia countries to Selic Corp Public Company Limited (Selic), a company focusing on bonding innovation serving various industries.

The sale included related manufacturing assets of the Ladlumkaew, Thailand, facility.

Neoplast and Neobun products, sold primarily in Thailand and Southeast Asia, were part of the Skin Health & Wellness business with 3M. The portfolios included sports and medical tapes, bandages and medicated products for the consumer and health care industry.

3M's active portfolio management strategy is focused on leveraging the strengths of 3M to create the greatest value for customers and delivering strong returns for shareholders. As part of ongoing strategic portfolio management, 3M has decided to exit these brands and prioritize other areas in the business, with a continued focus on Asia markets. Recent examples of 3M's portfolio management include the separation of the Food Safety business, the announced spin off of the Health Care business, and the acquisition of technology assets of LeanTec for the automotive aftermarket segment in the United States and Canada.

Selic has indicated that it intends to establish operations at the facility, including employment of interested site employees, to scale up production of Neoplast and Neobun brands and further product development for its medical device business.

The sale will not have a material impact on 3M's financial results.

Forward-Looking Statements

This news release contains forward-looking information about 3M's financial results and estimates and business prospects that involve substantial risks and uncertainties. You can identify these statements by the use of words such as 'anticipate,' 'estimate,' 'expect,' 'aim,' 'project,' 'intend,' 'plan,' 'believe,' 'will,' 'should,' 'could,' 'target,' 'forecast' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, regulatory, capital markets and other external conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) risks related to public health crises such as the global pandemic associated with the coronavirus (COVID-19); (3) foreign currency exchange rates and fluctuations in those rates; (4) liabilities related to certain fluorochemicals, including lawsuits concerning various PFAS-related products and chemistries, and claims and governmental regulatory proceedings and inquiries related to PFAS in a variety of jurisdictions; (5) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 2021, as updated by the Company's Current Report on Form 8-K dated April 26, 2022, and any subsequent quarterly reports on Form 10-Q (the 'Reports'); (6) competitive conditions and customer preferences; (7) the timing and market acceptance of new product offerings; (8) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (11) operational execution, including scenarios where the Company generates fewer productivity improvements than estimated; (12) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; (13) the Company's credit ratings and its cost of capital; (14) tax-related external conditions, including changes in tax rates, laws or regulations; (15) matters relating to the proposed spin-off of the Company's Health Care business, including whether the transaction will be completed, or if completed, will be on the expected terms; the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; the ability to satisfy the various closing conditions; potential business disruption; the diversion of management time; the impact of the transaction (or its pendency) on the Company's ability to retain talent; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the ability to realize the desired tax treatment (including whether an Internal Revenue Service private letter ruling will be sought or obtained); the risk that any consents or approvals required will not be obtained; risks associated with financings that may be undertaken and indebtedness that may be incurred in connection with the transaction and (16) matters relating to the voluntary chapter 11 proceedings of the Company's subsidiary Aearo Technologies and certain of its affiliates (the 'Aearo Entities'), including legal risks related to the chapter 11 proceedings; potential impacts to the Company's reputation and its relationships with customers, suppliers, employees, regulators and other counterparties and community members; potential impacts to the Company's liquidity or results of operations, including risks related to the amount that will be necessary to fully and finally resolve all of the Company's obligations to make payments to resolve such claims under the terms of its funding and indemnification agreement with the Aearo Entities and the Aearo Entities' ability to navigate the chapter 11 proceedings to obtain approval and consummation of a plan of reorganization.

About 3M

3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet.


Jennifer Ehrlich

Tel: 651-733-8805

Email: 3Mnews@mmm.com

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
3M COMPANY 0.79% 126.99 Delayed Quote.-28.51%
SELIC CORP -1.36% 2.9 End-of-day quote.-0.67%
All news about 3M COMPANY
11/30Dow dips ahead of Powell speech; Nasdaq kept afloat by growth stocks
11/303M Company Confirms Earnings Guidance for the Fourth Quarter of 2022
11/30Transcript : 3M Company Presents at Credit Suisse’s 10th Annual Global I..
11/18New 3M Ambulatory Potentially Preventable Complications software supports growing need ..
11/173M Announces Upcoming Investor Event
11/173M COMPANY : Ex-dividend day for
11/143m Co : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligat..
11/11Global markets live: SoftBank, Toshiba, Cisco, Apple, AstraZeneca...
11/103M Faces US Lawsuit From California Attorney General Over Toxic Pollutants
11/10DuPont de Nemours, 3M Face California Lawsuit Over Alleged Water Contamination
More news
Analyst Recommendations on 3M COMPANY
More recommendations
Financials (USD)
Sales 2022 34 250 M - -
Net income 2022 6 410 M - -
Net Debt 2022 11 642 M - -
P/E ratio 2022 11,3x
Yield 2022 4,69%
Capitalization 70 193 M 70 193 M -
EV / Sales 2022 2,39x
EV / Sales 2023 2,35x
Nbr of Employees 95 000
Free-Float 57,5%
Duration : Period :
3M Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 3M COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 20
Last Close Price 126,99 $
Average target price 134,78 $
Spread / Average Target 6,14%
EPS Revisions
Managers and Directors
Michael F. Roman Chairman & Chief Executive Officer
Monish Patolawala EVP, Chief Financial & Transformation Officer
John Patrick Banovetz Director-Industrial Adhesives & Tapes Division
Mark W. Murphy Executive VP, Chief Information & Digital Officer
Michael A. Duran Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
3M COMPANY-28.51%70 193
SIEMENS AG-11.78%111 519